Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Reims – page 16

418 clinical trials in Reims, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Reims at a glance
418
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

418 trials in Reims

Open in trial search

Oesophageal squamous cell carcinoma

Recruiting

Study Comparing Chemoradiotherapy with Fluorouracil, Cisplatin, and Carboplatin for Patients with Operable Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Karolinska University Hospital

Metastatic gastric cancer

Recruiting

Study on Dostarlimab Immunotherapy for Patients with Localized Gastric Cancer with Deficient Mismatch Repair or High Microsatellite Instability

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Association Gercor

Hormone-refractory prostate cancer

Recruiting

Study on the Effects of Acetylsalicylic Acid and Atorvastatin in Patients with Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Institut Gustave Roussy

Chronic lymphocytic leukaemia+1

Recruiting

Study on Ibrutinib and Venetoclax for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Biliary neoplasm

Recruiting

Study on Maintenance Therapy with Cisplatin, Durvalumab, and Trastuzumab for Patients with Advanced Biliary Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Unicancer

Gastrointestinal stromal tumour

Recruiting

Study on Imatinib and Atezolizumab for Patients with Advanced Gastrointestinal Stromal Tumors After Standard Treatments Fail

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Centre Leon Berard

Interstitial lung disease

Recruiting

Study on the Effectiveness and Safety of Rituximab for Patients with Progressive Interstitial Lung Disease with Inflammation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

General anaesthesia

Recruiting

Study on the Effects of Dexmedetomidine and Midazolam on Children's Experience After General Anesthesia

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Midazolam
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Adrenocortical carcinoma

Recruiting

Study on Mitotane Alone or with Cisplatin and Etoposide for Patients with High-Risk Adrenocortical Carcinoma After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Amsterdam UMC Stichting

Chronic kidney disease+1

Recruiting

Study on Blood Pressure Management with Amiloride Hydrochloride, Indapamide, and Furosemide for Patients with Uncontrolled Hypertension and Chronic Kidney Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Furosemide
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Acute lymphocytic leukaemia

Recruiting

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Anaplastic large cell lymphoma T- and null-cell types

Recruiting

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Vinblastine Sulfate
  • Sponsor:GPOH gGmbH

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Reims

What the registry says about research in the country

01 Oncology Studies

Groundbreaking research exploring treatments for various cancers, including multiple myeloma, colorectal cancer, and esophageal squamous cell carcinoma. Studies focus on evaluating novel therapies and combination treatments to improve patient outcomes.

  • Advanced pancreatic adenocarcinoma treatments
  • Breast cancer therapies
  • Prostate cancer management

Several trials investigate immunotherapy approaches and targeted treatments for specific genetic mutations.

02 Autoimmune Conditions

Clinical trials examining innovative treatments for autoimmune disorders, with particular focus on rheumatoid arthritis and psoriatic conditions. Research aims to evaluate new therapeutic approaches and optimize existing treatments.

  • Plaque psoriasis treatments
  • Rheumatoid arthritis maintenance therapy
  • Gout management strategies

Studies emphasize long-term efficacy and safety profiles of various treatment regimens.

03 Transplant Medicine

Advanced research in kidney transplantation focusing on preventing rejection and improving long-term outcomes. Studies evaluate new immunosuppressive strategies and monitoring protocols.

  • Antibody-mediated rejection prevention
  • Novel immunosuppressive protocols
  • Post-transplant monitoring techniques

Trials aim to optimize post-transplant care and reduce rejection rates.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.